Sign inCreate account

Report workspace

Add to folder
NCT06014073RECRUITINGanonymous

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Sponsor

Source record

Chinese PLA General Hospital

Phase

Source record

Phase 1/2

Modality

AI-normalized

cell therapy

Target

AI-normalized

CD19-targeting CAR-T cells with TRAC and Power3 (SPPL3) gene knock-out using CRISPR-Cas9 technology.

Indication / condition

AI-normalized

Non Hodgkin's Lymphoma

Intervention

Source record

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Cyclophosphamide

Related intelligence directories

Indication directory: Non Hodgkin's LymphomaModality directory: cell therapyTarget directory: CD19-targeting CAR-T cells with TRAC and Power3 (SPPL3) gene knock-out using CRISPR-Cas9 technology.

Source & freshness

Source record

NCT ID

NCT06014073

Original source

ClinicalTrials.gov

Source last updated

May 25, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06014073

Title

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Sponsor

Chinese PLA General Hospital

Status

RECRUITING

Phase

Phase 1/2

Condition raw

Non Hodgkin's Lymphoma

Condition normalized

Non Hodgkin's Lymphoma

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

CD19-targeting CAR-T cells with TRAC and Power3 (SPPL3) gene knock-out using CRISPR-Cas9 technology.

Target normalized

CD19-targeting CAR-T cells with TRAC and Power3 (SPPL3) gene knock-out using CRISPR-Cas9 technology.

Interventions

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Cyclophosphamide

Public preview

Source record

The ATHENA CAR-T therapy represents a novel approach in the treatment of refractory/relapsed B-cell non-Hodgkin lymphoma (NHL), leveraging allogeneic T cells with enhanced safety profiles due to gene editing. The market for CAR-T therapies is rapidly expanding, particularly in the oncology sector, with significant interest from major pharmaceutical companies. The competitive landscape includes established therapies like Kymriah and Yescarta, but ATHENA's unique gene editing may provide a differentiated offering. The study's recruitment status indicates ongoing interest and potential for rapid data generation, which could enhance its market positioning. Diligence should focus on regulatory pathways, potential manufacturing challenges, and the robustness of clinical data as it emerges.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell (ATHENA) Therapy in Adults With Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT06014073

Status

RECRUITING

Phase

Phase 1/2

Sponsor

Chinese PLA General Hospital

Executive brief

Investment-Ready Snapshot

The ATHENA CAR-T therapy represents a novel approach in the treatment of refractory/relapsed B-cell non-Hodgkin lymphoma (NHL), leveraging allogeneic T cells with enhanced safety profiles due to gene editing. The market for CAR-T therapies is rapidly expanding, particularly in the oncology sector, with significant interest from major pharmaceutical companies. The competitive landscape includes established therapies like Kymriah and Yescarta, but ATHENA's unique gene editing may provide a differentiated offering. The study's recruitment status indicates ongoing interest and potential for rapid data generation, which could enhance its market positioning. Diligence should focus on regulatory pathways, potential manufacturing challenges, and the robustness of clinical data as it emerges.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 25, 2025
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06014073

Indication

Non Hodgkin's Lymphoma

Modality

cell therapy

Target

CD19-targeting CAR-T cells with TRAC and Power3 (SPPL3) gene knock-out using CRISPR-Cas9 technology.

Intervention

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Cyclophosphamide

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.